These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38966990)

  • 1. Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities.
    McLaughlin VV; Sitbon O; Chin KM; Galiè N; Hoeper MM; Kiely DG; MacDonald G; Martin N; Mathai SC; Peacock A; Tawakol A; Torbicki A; Noordegraaf AV; Rosenkranz S
    Eur J Heart Fail; 2024 Jul; ():. PubMed ID: 38966990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.
    Grünig E; Jansa P; Fan F; Hauser JA; Pannaux M; Morganti A; Rofael H; Chin KM
    J Am Coll Cardiol; 2024 Jan; 83(4):473-484. PubMed ID: 38267108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
    Chin KM; Sitbon O; Doelberg M; Feldman J; Gibbs JSR; Grünig E; Hoeper MM; Martin N; Mathai SC; McLaughlin VV; Perchenet L; Poch D; Saggar R; Simonneau G; Galiè N
    J Am Coll Cardiol; 2021 Oct; 78(14):1393-1403. PubMed ID: 34593120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The REPAIR Study: Effects of Macitentan on RV Structure and Function in Pulmonary Arterial Hypertension.
    Vonk Noordegraaf A; Channick R; Cottreel E; Kiely DG; Marcus JT; Martin N; Moiseeva O; Peacock A; Swift AJ; Tawakol A; Torbicki A; Rosenkranz S; Galiè N
    JACC Cardiovasc Imaging; 2022 Feb; 15(2):240-253. PubMed ID: 34801462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
    Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
    Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
    Martynyuk TV; Aleevskaya AM
    Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats.
    Mamazhakypov A; Weiß A; Zukunft S; Sydykov A; Kojonazarov B; Wilhelm J; Vroom C; Petrovic A; Kosanovic D; Weissmann N; Seeger W; Fleming I; Iglarz M; Grimminger F; Ghofrani HA; Pullamsetti SS; Schermuly RT
    Pulm Circ; 2020; 10(4):2045894020947283. PubMed ID: 33240483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Left Heart Disease Risk Factors on Outcomes in Pulmonary Arterial Hypertension Therapy.
    Kearney K; Brown K; Celermajer DS; Collins N; Cordina R; Corrigan C; Dwyer N; Feenstra J; Keating D; Keogh A; Kotlyar E; Lavender M; McWilliams T; Williams T; Whitford H; Weintraub R; Wrobel J; Ellender C; Anderson J; Lau EM;
    Chest; 2024 Apr; 165(4):967-977. PubMed ID: 37951349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension.
    Souza R; Delcroix M; Galié N; Jansa P; Mehta S; Pulido T; Rubin L; Sastry BKS; Simonneau G; Sitbon O; Torbicki A; Boyanova N; Chamitava L; Stein C; Channick RN
    Adv Ther; 2022 Sep; 39(9):4374-4390. PubMed ID: 35819570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
    Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Vachiery JL; Grünig E; Oudiz RJ; Vonk-Noordegraaf A; White RJ; Blair C; Gillies H; Miller KL; Harris JH; Langley J; Rubin LJ;
    N Engl J Med; 2015 Aug; 373(9):834-44. PubMed ID: 26308684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
    Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
    BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of macitentan for the treatment of pulmonary hypertension: Real-world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS).
    McLaughlin VV; Channick R; Kim NH; Frantz RP; McConnell JW; Melendres-Groves L; Miller C; Ravichandran A; Rodriguez-Lopez J; Brand M; Leroy S; Wetherill G; Chin KM
    Pulm Circ; 2022 Oct; 12(4):e12150. PubMed ID: 36381290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.
    Momoi M; Hiraide T; Shinya Y; Momota H; Fukui S; Kawakami M; Itabashi Y; Fukuda K; Kataoka M
    Ther Adv Respir Dis; 2021; 15():1753466621995048. PubMed ID: 33627044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).
    D'Alto M; Romeo E; Argiento P; Paciocco G; Prediletto R; Ghio S; Correale M; Lo Giudice F; Badagliacca R; Greco A; Vizza CD
    J Cardiovasc Med (Hagerstown); 2018 Jan; 19(1):12-17. PubMed ID: 29215546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset.
    Channick R; Chin KM; McLaughlin VV; Lammi MR; Zamanian RT; Turricchia S; Ong R; Mitchell L; Kim NH
    Cardiol Ther; 2024 Jun; 13(2):315-339. PubMed ID: 38451426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial.
    McLaughlin VV; Vachiery JL; Oudiz RJ; Rosenkranz S; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Peacock AJ; Simonneau G; Rubin LJ; Blair C; Langley J; Hoeper MM;
    J Heart Lung Transplant; 2019 Dec; 38(12):1286-1295. PubMed ID: 31648845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
    Kuwana M; Blair C; Takahashi T; Langley J; Coghlan JG
    Ann Rheum Dis; 2020 May; 79(5):626-634. PubMed ID: 32161055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study)　- Protocol of a Multicenter Randomized Control Trial.
    Akagi S; Dohi Y; Ishikawa K; Kubota K; Horimoto K; Yagi S; Hirata T; Yamamoto E; Ito H; Nakamura K
    Circ Rep; 2021 Jan; 3(2):105-109. PubMed ID: 33693297
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension.
    White RJ; Vonk-Noordegraaf A; Rosenkranz S; Oudiz RJ; McLaughlin VV; Hoeper MM; Grünig E; Ghofrani HA; Chakinala MM; Barberà JA; Blair C; Langley J; Frost AE
    Respir Res; 2019 Sep; 20(1):208. PubMed ID: 31511080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.
    Jansa P; Pulido T
    Am J Cardiovasc Drugs; 2018 Feb; 18(1):1-11. PubMed ID: 29280064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.